Serological Markers of Blood Borne Viruses among Persons with Combined Factor V and VIII Deficiency
Hassan Mansouritorghabeh
1
, *
,
Reza Farid Hosseini
2
,
Aliakbar Pourfathollah
3
and
Azizollah Behjati
2
1 Immunology Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, mansouritorghabe@mums.ac.ir, Khorasan-e-Razavi, IR.Iran
2 Immunology Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Khorasan-e-Razavi, IR.Iran
3 Experimental Hematology and Blood Banking Group, Medical Sciences School, Tarbiat Modarres University (TMU), Tehran, IR.Iran
*
Immunology Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, mansouritorghabe@mums.ac.ir, Khorasan-e-Razavi, IR.Iran. Tel: +98 511 8012761. Fax: +98 512 4225157. Email:
mansouritorghabe@mums.ac.ir
Hepatitis Monthly: ,
8 (3) ; 221-224 Article Type: Brief Report
Received:
May 4, 2008
Accepted:
July 13, 2008
To Cite:
Mansouritorghabeh
H, Hosseini
R, Pourfathollah
A, Behjati
A. Serological Markers of Blood Borne Viruses among Persons with Combined Factor V and VIII Deficiency,
Hepat Mon.
Online ahead of Print
;8(3):221-224.
Abstract
Background and Aims: Combined factor V and VIII deficiency (CF5F8D) is a rare hemorrhagic disorder. Treatment of patients with blood products has been associated with infections with blood-borne viruses. Due to absence of any survey on status of blood borne viruses in individuals with CF5F8D, we tried to address this question.
Methods: Among 25 known cases, 24 individuals were assessed for hepatitis B and C viruses (HBV & HCV), human T lymphotropic virus type one (HTLV-I) and human immunodeficiency virus type1/2 (HIV1/2) using enzyme linked immunosorbent assay method.
Results: In the group under survey, 2 cases (8.3%) were positive for anti-HCV. There was no infection with HBV, HTLV-I and HIV.
Conclusions: Hepatitis C is a major health problem in CF5F8D, as in hemophiliacs, and may need more attention from manufacturers of blood products and more careful pre-transfusion screening of blood products for anti-HCV.
© 0, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Except where otherwise noted, this work is licensed under
Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments